|Bid||53.979 x 100000|
|Ask||54.051 x 100000|
|Day's range||53.510 - 53.882|
|52-week range||53.060 - 63.340|
|PE ratio (TTM)||29.08|
|Forward Dividend & Yield||N/A (N/A)|
|1y target est||N/A|
Insurers could pay $275 million (209.06 million pounds) to cover the insured portion of drugmaker Merck & Co's loss from a cyber attack in June, according to a forecast by Verisk Analytics Inc's Property Claim Services (PCS) unit. Merck, however, has not disclosed the magnitude of its uninsured losses from the "NotPetya" attack, which disrupted production of some Merck medicines and vaccines. "Merck has not yet fully quantified its losses, much less given any of its insurers an estimate of the total amount of those losses," Merck spokeswoman Claire Gillespie said in a statement.
Insurers could pay $275 million to cover the insured portion of drugmaker Merck & Co's loss from a cyber attack in June, according to a forecast by Verisk Analytics Inc's Property Claim Services unit. ...
Is Wall Street underestimating Keytruda? Shares of Merck& Co. ( MRK) popped today after Citigroup’s Andrew Baum upgraded the drug maker to Buy from Neutral, and hiked his price target from $65 a share to $72 a share, citing heightened expectations for the blockbuster cancer drug. It’s been a volatile 2017 for Merck.
The first placebo-controlled study of two vaccines against the Ebola virus found they both successfully created a powerful antibody response for a year, suggesting they both could be tools to save lives ...
Global Healthcare Investment Advisors LLC wants to generate more than just healthy financial returns with its deals. The New York-based firm, which does business as the Global Health Investment Fund, also ...
Merck & Co. is halting development of new hepatitis C treatments after reviewing their effectiveness and determining an abundance of treatments were already available.
Bristol-Myers Squibb (BMY), a US pharmaceutical company, includes innovative products from its Cardiovascular, Immunoscience, Neuroscience, Oncology, and Virology franchises.
Merck & Co. said Friday it would discontinue the development of the investigational combination regimens MK-3682B and MK-3682C for the treatment of chronic hepatitis C, after a review of available Phase ...
Giving Merck & Co's immunotherapy drug Keytruda in combination with chemotherapy for previously untreated advanced lung cancer appears to provide durable benefits, according to an update of a closely watched clinical trial. U.S. regulators approved the drug cocktail in May but the limited clinical trial data to date means that questions still remain as to whether it will retain its effectiveness over time.
After last month's big clinical trial setback in lung cancer, AstraZeneca will seek to rebuild its oncology reputation next week when it unveils full details of two key clinical trials tackling the disease ...
Kenneth Frazier, the Merck (LSE: 0O14.L - news) chief executive who has resigned from President Trump's Manufacturing Council, has an inspiring story that encapsulates the American Dream. Mr Frazier's grandfather was a South Carolina sharecropper, working in the system set up following the American Civil War under which landowners allowed tenant farmers to use their land in exchange for a portion of the crop.
Merck (Jakarta: 28586808.JK - news) & Co Inc Chief Executive Kenneth Frazier resigned from U.S. President Donald Trump's American Manufacturing Council on Monday, saying he was taking a stand against intolerance and extremism. Trump denounced neo-Nazis and the Ku Klux Klan as criminals and thugs on Monday, bowing to mounting political pressure after initially saying many sides were to blame after a white-nationalist rally turned deadly in Virginia. Frazier, who is African-American, is the only CEO so far to leave one of Trump's advisory councils because of his reaction to the violence in Virginia.
NEW YORK/LAS VEGAS, July 28 (Reuters) - Drug and vaccine maker Merck (Jakarta: 28586808.JK - news) & Co Inc said it suffered a worldwide disruption of its operations when it was the victim of an international cyber attack in June, halting production of its drugs, which will hurt its profits for the rest of the year. The company said it does not yet understand the full magnitude of the impact as it is in the process of restoring manufacturing operations. Merck (LSE: 0O14.L - news) said it was confident that it will be able to maintain a continuous supply of its top-selling and life-saving drugs, including cancer drug Keytruda, diabetes drug Januvia and hepatitis C drug Zepatier.
Bristol-Myers Squibb Co shares fell 4 percent on Thursday as investors bet that a failed cancer-drug trial at AstraZeneca Plc (NYSE: AZN - news) would have negative implications for Bristol-Myers' similar immunotherapy treatment regimen. AstraZeneca's Mystic study, released Thursday, looked at a combination of immune system-boosting drugs to treat non-small cell lung cancer (NSCLC). Bristol-Myers is studying a similar combination of its two top drugs in the same therapy class, Opdivo and Yervoy.
AstraZeneca's combination of two injectable immunotherapy drugs failed to help patients as hoped in a closely watched advanced lung cancer trial, triggering the biggest ever daily fall in its shares on Thursday. The so-called Mystic study was the industry's most anticipated clinical experiment this year and the news saw the shares fall 16 percent, wiping some $14 billion off AstraZeneca's value.
The threat of slowing demand and new competition in GlaxoSmithKline (Other OTC: GLAXF - news) 's flagship HIV drug business unnerved investors in Britain's biggest drugmaker on Wednesday, sending its shares down as much as 1.8 percent. GSK pared losses to 0.8 percent by 1220 GMT but remained among the top losers in London's FTSE-100 index after Citigroup (Swiss: C-USD.SW - news) downgraded the stock to neutral from buy and cut earnings forecasts by up to 9 percent. HIV medicines, which GSK sells through its ViiV Healthcare unit, have been star performers in recent years and new CEO Emma Walmsley said in April that the "HIV portfolio continues to go from strength to strength".
MOSCOW/KIEV/WASHINGTON, June 27 (Reuters) - A major global cyber attack on Tuesday disrupted computers at Russia's biggest oil company, Ukrainian banks and multinational firms with a virus similar to the ransomware that last month infected more than 300,000 computers. The rapidly spreading cyber extortion campaign underscored growing concerns that businesses have failed to secure their networks from increasingly aggressive hackers, who have shown they are capable of shutting down critical infrastructure and crippling corporate and government networks.
Britain's competition watchdog has accused Merck & Co (Swiss: MRK-USD.SW - news) of operating an unfair discount scheme for its medicine Remicade that it said was designed to restrict competition from so-called biosimilar copies. The Competition and Markets Authority (CMA) said on Tuesday it had provisionally found the U.S. company's European unit, Merck Sharp & Dohme, had abused its dominant position through the scheme, opening it up to potential financial penalties.
Sales forecasts for AstraZeneca's all-important new cancer immunotherapy drug Imfinzi are set to rise after the drugmaker received an unexpectedly early boost for the medicine in lung cancer last week. ...
A trial of AstraZeneca's key immunotherapy drug durvalumab showed it reduced disease progression in lung cancer patients, sending the company's shares higher and giving it a lead over rivals as it seeks to transform its oncology business. The trial results are an unexpectedly early boost for the product, known commercially as Imfinzi, which the company hopes will become a blockbuster drug with sales in the billions of dollars. It sets AstraZeneca apart from rivals Merck (LSE: 0O14.L - news) and Roche, whose equivalent drugs are years behind in the race for similar treatments against lung cancer.